## Registered Office: Kathali, Bhaluka, Mymensingh (Factory premises) 2<sup>nd</sup> QUARTER STATEMENT OF FINANCIAL POSITION (Un-audited) STATEMENT OF CHANGES IN EQUITY (Un-audited) For the 2<sup>nd</sup> Quarter ended 31<sup>st</sup> December 2021 As at 31st December 2021 Amount in Tk. Particulars 31-Dec-21 30-Jun-21 ASSETS Balance as at Non-current assets: 1st July, 2021 Net Profit after t 2,310,000,000 1,408,262,744 5,503,099 (1,802,654) 1,633,199,764 5,355,162,953 2,928,345,134 2,881,685,287 Property, plant and equipment 645,046,027 437,216,157 Capital work-in-progress for the period 598,299,976 598,299,976 1,009,350 874,770 3,574,400,511 3,319,776,214 Investment in shares Total non-current assets Current assets: of Machinery Dep. Adjustment on Revaluation Reserve Deferred Tax on 1,436,613,651 1,278,652,519 Inventories 2,525,942,586 1,933,404,526 1,277,840,046 1,016,340,954 Trade and other receivables Advance deposits and prepayments Deferred tax assets 184,897,000 239,978,713 737,754,987 5,872,256 154,842,383 6,323,762,908 5,215,795,475 Short term loan Investment in FDR 2,310,000,000 1,322,429,380 5,503,099 (1,668,074) 1,970,833,104 5,607,097,509 Cash and cash equivalents Total current assets 9,898,163,419 8,535,571,691 EQUITY AND LIABILITIES Equity attributable to equity holders of the company: 2,310,000,000 2,310,000,000 Share capital STATEMENT OF CHANGES IN EQUITY (Un-audited) For the 2<sup>nd</sup> Quarter ended 31<sup>st</sup> December 2020 1,322,429,381 1,408,262,744 Revaluation surplus Tax holiday reserve 5,503,099 5,503,099 Available sale reserve (1,668,074) (1,802,654) Retained earnings Total equity attributable to equity holders of the company 5,607,097,510 5,355,162,954 Non-current liabilities: 359,647,233 387,746,623 359,647,233 387,746,623 Long term loan Balance as at 2,310,000,000 1,583,657,104 5,503,099 (2,050,679) 733,236,109 4,630,345,633 Total non-current liabilities Current liabilities: for the period 144,009,620 225,895,398 Current Portion of long term loan 2,756,730,262 1,883,561,131 Short term bank loan Share application money refundable 4,323,613 4,323,613 of Machinery Dep. Adjustment on Revaluation Reserve Deferred Tax on 115,854,978 115,854,978 Trade Pavables 12.308.304 215.849.663 Accrued expenses 166,127,281 (28,963,745) (144,818,723) VAT Payable Liabilities for EWF & WPPF 15,596,253 11,250,237 100,124,314 58,577,255 9,459,956 79,239,093 Provision for employee's provident fund 23.003.728 80,309,165 Provision for gratuity Dividend payable 512,218,300 191,702,535 Income tax payable 131,281,681 (2.098.102)Total current liabilities 3,931,418,676 2,792,662,114 4,291,065,909 9,898,163,419 8,535,571,691 Total liabilities Total equity and liabilities Net Assets Value per Share (par value Tk. 10 each) 24.27 23.18 Company Secretary Managing Director (Drest) Nucun Nahan Karim Chairman STATEMENT OF CASH FLOW (Un-audited) STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-audited) For the 2<sup>nd</sup> Quarter ended 31<sup>st</sup> December 2021 For the 2<sup>nd</sup> Quarter ended 31<sup>st</sup> December 2021 Amount in Tk. 31-Dec-20 July to Dec'21 July to Dec'20 Oct to Dec'21 **Particulars** Oct to Dec'20 Particulars 31-Dec-21 Half Yearly Half Yearly 2<sup>nd</sup> Quarter 2<sup>nd</sup> Quarter 3,750,177,399 3,751,253,501 Collection from customers Turnover (Net of VAT) 3,730,620,143 2,077,817,961 2,183,576,358 4,342,715,459 (3,693,537,086) (141,416,354) (87,877,706) Cash paid to suppliers & others Less: Cost of goods sold (2,036,616,104) **Gross profit** 2,306,099,355 (1.911.569.761) Interest paid 2,306,099,355 1,819,050,382 1,069,115,121 Income tax paid (42.992.507) Operating expenses: (110,815,708) Net cash generated from operations Marketing, Selling and Distribution expenses (1,131,260,701) (1,164,496,860) Administrative expenses (166,899,263) (147,079,846) (570,167,375) (88,077,953) (616,215,915) (75,113,110) Cash flows from investing activities: Acquisition of Property, Plant and Equips Short term investment received/(paid) Investment in FDR Total operating expenses (1.298.159.964) (1.311.576.706) (658,245,328) (691,329,024)

Operating profit: Financial expense

Other income Profit before WPPF

Contribution to WPPF

Tax expenses
Current tax

Deferred tax

Net profit before tax

Net profit after tax for the period 598,299,976 

1,007,939,391 (141,416,354)

18,703,767

885,226,805 (42,153,657)

843,073,147

(55,081,713) (244,773,171)

**507,473,676** (87,877,706)

**420,766,592** (20,036,504)

400,730,088

(9,551,755)

(109,734,277) 290,995,811

291,025,144 231,000,000

29,333

1.26

1,170,622

410,869,793 (63,003,258)

13,574,209

344,229,280 315,693,471

**331,478,144** (15,784,673)

(2,920,394)

(25,622)

1.01

(81,843,762) 233,849,709

233,824,087

**361,440,744** (17,211,464)

(20,444,793) (97,896,381) 246,332,899

(218,693) 246,114,207 231,000,000

Managing Director

(334,047,992)

(792,428,309)

(25,984,235)

(109,985,168)

737,199,727

154,842,383 231,000,000

Managing Director

Nieum Noller Karin
Chairman

(41,399,837)

(15,632,985)

(15,857,736)

(168,073,281) 598,780,839

430,707,558

231,000,000

(0.48)

Interest and other received

Net cash from/(used in) investing activities

Short term loan received/(paid)

Net cash from/(used in) financing activities

Cash and cash equivalents-Closing balance

Net Increase/(decrease) in cash and cash equivalents (182,997,129)
Cash and cash equivalents-Opening balance 337,839,512

Net operating cash flows per share (par value Tk. 10 each) (0.55)

Cash Flows from Financing Activities:
Dividend paid

Long term loan received/(paid)

Number of Shares

**BEACON**<sup>®</sup> Pharmaceuticals Limited